-1280x720-800x450.jpg)
- Biomind Labs (BMND) announced positive initial results from the first part of its Phase II trial for treatment-resistant depression
- The subject of the trial is its BMND01 candidate, a novel liquid inhaled formulation of N, N-Dimethyltryptamine (DMT)
- The trial involved doses ranging from 5 to 100 mg. No volunteer presented serious adverse events or clinical risk to the 11 different doses tested
- Biomind Labs Inc. (BMND) is up 30.21 per cent, trading at $1.25 per share as of 11:50 am ET
Biomind Labs (BMND) announced positive initial results from the first part of its Phase II trial for treatment-resistant depression.
The subject of the trial is its BMND01 candidate, a novel liquid inhaled formulation of N, N-Dimethyltryptamine (DMT).
The trial involved doses ranging from 5 to 100 mg. No volunteer presented serious adverse events or clinical risk to the 11 different doses tested.
Biomind Labs’ Head of the Psychiatric Research Unit, Marcelo Falchi, M.D., explained that during the trial, the team observed only a mild, transient, and self-limited increase in blood pressure and heart rate of up to 30 per cent compared to baseline values, with no clinical repercussions. He called it a physiological increase comparable to moderate physical activity in healthy people.
“The only endogenous psychedelic molecule, which is already present in low concentrations in different organs of the human body.”
The experimental design of this open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry.
This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards.
Biomind Labs’ CEO, Alejandro Antalich, said that with the conclusion of the dosing sessions, 30 volunteers went through the activities of the proprietary clinical-experimental protocol developed by our scientific team to verify the safety and tolerability of the novel DMT-based candidate BMND01 and protocol in healthy people.
“This is the world’s first in-lab study using an inhaled formulation of DMT and the largest completed trial with this molecule. We are seeking to tackle one of the most concerning factors related to psychedelics as a potential novel treatment for mental health disorders, the long duration of the sessions. This trial aims to go through the full psychedelic experience in just 10 minutes. These successful first results bring strong potential for the next phase of the trial, which will address patients suffering from treatment-resistant depression”
Biomind Labs (BMND) is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. The company’s focus is to guarantee patients access to affordable and modern-day treatments and use cases.
Biomind Labs Inc. (BMND) is up 30.21 per cent, trading at $1.25 per share as of 11:50 am ET.